Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy

This study aims to identify baseline medications that, as a proxy for the diseases they are dispensed for, are associated with increased risk of mortality in COVID-19 patients from two regions in Spain and Italy using real-world data. We conducted a cross-country, retrospective, observational study...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kevin Bliek-Bueno, Sara Mucherino, Beatriz Poblador-Plou, Francisca González-Rubio, Mercedes Aza-Pascual-Salcedo, Valentina Orlando, Mercedes Clerencia-Sierra, Ignatios Ioakeim-Skoufa, Enrico Coscioni, Jonás Carmona-Pírez, Alessandro Perrella, Ugo Trama, Alexandra Prados-Torres, Enrica Menditto, Antonio Gimeno-Miguel
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 medications drugs mortality real-world data Medicine R
Acceso en línea:	https://doaj.org/article/f9949d5945104aa6931784fdf5b6e67a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f9949d5945104aa6931784fdf5b6e67a
record_format	dspace
spelling	oai:doaj.org-article:f9949d5945104aa6931784fdf5b6e67a2021-11-25T17:48:21ZBaseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy10.3390/ijerph1822117861660-46011661-7827https://doaj.org/article/f9949d5945104aa6931784fdf5b6e67a2021-11-01T00:00:00Zhttps://www.mdpi.com/1660-4601/18/22/11786https://doaj.org/toc/1661-7827https://doaj.org/toc/1660-4601This study aims to identify baseline medications that, as a proxy for the diseases they are dispensed for, are associated with increased risk of mortality in COVID-19 patients from two regions in Spain and Italy using real-world data. We conducted a cross-country, retrospective, observational study including 8570 individuals from both regions with confirmed SARS-CoV-2 infection between 4 March and 17 April 2020, and followed them for a minimum of 30 days to allow sufficient time for the studied event, in this case death, to occur. Baseline demographic variables and all drugs dispensed in community pharmacies three months prior to infection were extracted from the PRECOVID Study cohort (Aragon, Spain) and the Campania Region Database (Campania, Italy) and analyzed using logistic regression models. Results show that the presence at baseline of potassium-sparing agents, antipsychotics, vasodilators, high-ceiling diuretics, antithrombotic agents, vitamin B12, folic acid, and antiepileptics were systematically associated with mortality in COVID-19 patients from both countries. Treatments for chronic cardiovascular and metabolic diseases, systemic inflammation, and processes with increased risk of thrombosis as proxies for the conditions they are intended for can serve as timely indicators of an increased likelihood of mortality after the infection, and the assessment of pharmacological profiles can be an additional approach to the identification of at-risk individuals in clinical practice.Kevin Bliek-BuenoSara MucherinoBeatriz Poblador-PlouFrancisca González-RubioMercedes Aza-Pascual-SalcedoValentina OrlandoMercedes Clerencia-SierraIgnatios Ioakeim-SkoufaEnrico CoscioniJonás Carmona-PírezAlessandro PerrellaUgo TramaAlexandra Prados-TorresEnrica MendittoAntonio Gimeno-MiguelMDPI AGarticleCOVID-19medicationsdrugsmortalityreal-world dataMedicineRENInternational Journal of Environmental Research and Public Health, Vol 18, Iss 11786, p 11786 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 medications drugs mortality real-world data Medicine R
spellingShingle	COVID-19 medications drugs mortality real-world data Medicine R Kevin Bliek-Bueno Sara Mucherino Beatriz Poblador-Plou Francisca González-Rubio Mercedes Aza-Pascual-Salcedo Valentina Orlando Mercedes Clerencia-Sierra Ignatios Ioakeim-Skoufa Enrico Coscioni Jonás Carmona-Pírez Alessandro Perrella Ugo Trama Alexandra Prados-Torres Enrica Menditto Antonio Gimeno-Miguel Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy
description	This study aims to identify baseline medications that, as a proxy for the diseases they are dispensed for, are associated with increased risk of mortality in COVID-19 patients from two regions in Spain and Italy using real-world data. We conducted a cross-country, retrospective, observational study including 8570 individuals from both regions with confirmed SARS-CoV-2 infection between 4 March and 17 April 2020, and followed them for a minimum of 30 days to allow sufficient time for the studied event, in this case death, to occur. Baseline demographic variables and all drugs dispensed in community pharmacies three months prior to infection were extracted from the PRECOVID Study cohort (Aragon, Spain) and the Campania Region Database (Campania, Italy) and analyzed using logistic regression models. Results show that the presence at baseline of potassium-sparing agents, antipsychotics, vasodilators, high-ceiling diuretics, antithrombotic agents, vitamin B12, folic acid, and antiepileptics were systematically associated with mortality in COVID-19 patients from both countries. Treatments for chronic cardiovascular and metabolic diseases, systemic inflammation, and processes with increased risk of thrombosis as proxies for the conditions they are intended for can serve as timely indicators of an increased likelihood of mortality after the infection, and the assessment of pharmacological profiles can be an additional approach to the identification of at-risk individuals in clinical practice.
format	article
author	Kevin Bliek-Bueno Sara Mucherino Beatriz Poblador-Plou Francisca González-Rubio Mercedes Aza-Pascual-Salcedo Valentina Orlando Mercedes Clerencia-Sierra Ignatios Ioakeim-Skoufa Enrico Coscioni Jonás Carmona-Pírez Alessandro Perrella Ugo Trama Alexandra Prados-Torres Enrica Menditto Antonio Gimeno-Miguel
author_facet	Kevin Bliek-Bueno Sara Mucherino Beatriz Poblador-Plou Francisca González-Rubio Mercedes Aza-Pascual-Salcedo Valentina Orlando Mercedes Clerencia-Sierra Ignatios Ioakeim-Skoufa Enrico Coscioni Jonás Carmona-Pírez Alessandro Perrella Ugo Trama Alexandra Prados-Torres Enrica Menditto Antonio Gimeno-Miguel
author_sort	Kevin Bliek-Bueno
title	Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy
title_short	Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy
title_full	Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy
title_fullStr	Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy
title_full_unstemmed	Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy
title_sort	baseline drug treatments as indicators of increased risk of covid-19 mortality in spain and italy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f9949d5945104aa6931784fdf5b6e67a
work_keys_str_mv	AT kevinbliekbueno baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT saramucherino baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT beatrizpobladorplou baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT franciscagonzalezrubio baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT mercedesazapascualsalcedo baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT valentinaorlando baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT mercedesclerenciasierra baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT ignatiosioakeimskoufa baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT enricocoscioni baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT jonascarmonapirez baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT alessandroperrella baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT ugotrama baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT alexandrapradostorres baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT enricamenditto baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly AT antoniogimenomiguel baselinedrugtreatmentsasindicatorsofincreasedriskofcovid19mortalityinspainanditaly
_version_	1718412022325968896

Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy

Ejemplares similares